Jong-In Park

12PUBLICATIONS
30CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Social epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 08, 2026
Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.

|Jan 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.

April K S Salama, Victoria Wang, Erin R Macrae

|Jun 27, 2024
Estrogen-related receptor alpha promotes thyroid tumor cell survival via a tumor subtype-specific regulation of target gene networks.

Wenjing Chen, Young Shin Song, Han Sai Lee

|Feb 20, 2024
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.

Wenjing Chen, Sophie Dream, Pui-Yin Leung

|Oct 14, 2023
Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.

Wenjing Chen, Jong-In Park

|Jun 10, 2023
MAPK-ERK Pathway.

Jong-In Park

Pageof 2

Frequent Collaborators

3 joint publications

Pui-Kei Wu

2 joint publications

Wenjing Chen

1 joint publications

Rebekah L Gundry

1 joint publications

Hao Shao